Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose–Response
Cardiovascular Drugs and Therapy · 2023-08 · 37 (4) · 695-703
DOI: 10.1007/s10557-022-07322-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 17.02.2022. Verfasst von Fernando Scudiero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Sciences Departement, Cardiology Unit, ASST Bergamo Est, Bolognini Hospital, Seriate, BG, Italy. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This study aims to assess the association between body mass index (BMI) and platelet reactivity in STEMI patients treated with oral 3rd generation P2Y12 inhibitors. METHODS: Overall, 429 STEMI patients were enrolled in this study. Patients were divided into two groups according to BMI (BMI < 25 vs ≥ 25 kg/m2). A propensity score matching (1:1) was performed to balance potential confounders in patient baseline characteristics. Platelet reactivity was assessed by VerifyNow at baseline and after 3rd generation P2Y12 inhibitor (ticagrelor or prasugrel) loading dose (LD). Blood samples were obtained at baseline (T0), 1 h (T1), 2 h (T2), 4-6 h (T3), and 8-12 h (T4) after the LD. High on-treatment platelet reactivity (HTPR) was defined as a platelet reactivity unit value ≥ 208 units. RESULTS: After propensity score matching, patients with BMI ≥ 25 had similar values of baseline platelet reactivity, while they had higher level of platelet reactivity at 1 and 2 h after the LD and higher rate of HRPT. Furthermore, multivariate analysis demonstrated that BMI ≥ 25 was an independent predictor of HTPR at 2 h (OR 2.01, p = .009). Conversely, starting from 4 h after the LD, platelet reactivity values and HRPT rates were comparable among the two study groups. CONCLUSIONS: A BMI ≥ 25 kg/m2 is associated with delayed pharmacodynamic response to oral 3rd generation P2Y12 inhibitor LD, and it is a strong predictor of HTPR in STEMI patients treated by dual antiplatelet therapy with ticagrelor or prasugrel.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Sciences Departement, Cardiology Unit, ASST Bergamo Est, Bolognini Hospital, Seriate, BG, Italy.
- Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
- Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy.
- Cardiology Unit, ASL4 Liguria, Ospedali del Tigullio, Polo Di Lavagna, GE, Italy.
- Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi (Salerno), Italy.
- Department of Internal Medicine and Medical Specialties (DIMI) Clinic of Cardiovascular Diseases, University of Genoa, Genoa, Italy.
Zitieren
APA
Scudiero, F., Canonico, M. E., Sanna, G. D., Dossi, F., Silverio, A., Galasso, G., Esposito, G., Porto, I., & Parodi, G. (2023). Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose–Response. Cardiovascular Drugs and Therapy, 37(4), 695-703. https://doi.org/10.1007/s10557-022-07322-2
Vancouver
Scudiero F, Canonico ME, Sanna GD, Dossi F, Silverio A, Galasso G, et al. Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose–Response. Cardiovascular Drugs and Therapy. 2023;37(4):695-703. doi:10.1007/s10557-022-07322-2
BibTeX
@article{Scudiero2023,
author = {Scudiero, Fernando and Canonico, Mario E and Sanna, Giuseppe D and Dossi, Filippo and Silverio, Angelo and Galasso, Gennaro and Esposito, Giovanni and Porto, Italo and Parodi, Guido},
title = {Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose–Response},
journal = {Cardiovascular Drugs and Therapy},
year = {2023},
volume = {37},
number = {4},
pages = {695--703},
doi = {10.1007/s10557-022-07322-2}
}
EUVIMED